Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
The potential link between GLP-1 therapies and atrial fibrillation is drawing increasing clinical interest as cardiometabolic care continues to evolve. Patients with type 2 diabetes face a significantly higher risk of atrial fibrillation, yet GLP-1 receptor agonists are rarely discussed in rhythm management conversations. Could medications such as semaglutide (Ozempic), …
Read More »GLP-1s and Atrial Fibrillation: What Do the Data Suggest?
